236 related articles for article (PubMed ID: 31800598)
1. Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Ghaffar M; Orr C; Webb G
PLoS One; 2019; 14(12):e0225701. PubMed ID: 31800598
[TBL] [Abstract][Full Text] [Related]
2. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
4. Cryptococcus neoformans/Cryptococcus gattii species complex melanized by epinephrine: Increased yeast survival after amphotericin B exposure.
Brilhante RSN; Rocha MGD; Oliveira JS; Pereira-Neto WA; Guedes GMM; Cordeiro RA; Sidrim JJC; Rocha MFG; Castelo-Branco DSCM
Microb Pathog; 2020 Jun; 143():104123. PubMed ID: 32169493
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
6. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.
Bauer M; Thomas AM; Larsen RA
Mycopathologia; 2012 Jun; 173(5-6):435-43. PubMed ID: 22322619
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
Chandenier J; Adou-Bryn KD; Douchet C; Sar B; Kombila M; Swinne D; Thérizol-Ferly M; Buisson Y; Richard-Lenoble D
Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):506-8. PubMed ID: 15141336
[TBL] [Abstract][Full Text] [Related]
11. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
12. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro.
Martinez LR; Casadevall A
Antimicrob Agents Chemother; 2006 Mar; 50(3):1021-33. PubMed ID: 16495265
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Nooney L; Matthews RC; Burnie JP
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
[TBL] [Abstract][Full Text] [Related]
16. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.
Venkateswarlu K; Taylor M; Manning NJ; Rinaldi MG; Kelly SL
Antimicrob Agents Chemother; 1997 Apr; 41(4):748-51. PubMed ID: 9087482
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
19. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
